THE LANCET Infectious Diseases

Supplementary webappendix

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.


Supplement to: Olotu A, Lusingu J, Leach A, et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial . *Lancet Infect Dis* 2011; published online Jan 14. DOI:10.1016/S1473-3099(10)70262-0.


Supplementary Figure 1 Legend

Anti-CS titres with interpolated fit of log-transformed values (3=1000 EU/mL, 2=100 EU/mL, 1=10 EU/mL, 0=1 EU/mL). Time=0 is 1 month after the final vaccination.

Supplementary Figure 2 Legend

For each model, anti-CS titres were divided into two groups, above and below a dichotomization point (x axis) and goodness of fit for each model measured (log likelihood, y axis).





Supplementary figure 2: Goodness fit log likelihood and dichotomization point for anti-CS

